Cargando…
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
BACKGROUND: Bevacizumab remains the most widely used and most thoroughly characterized angiogenesis inhibitor for a range of advanced cancers. Bevacizumab-bvzr (Zirabev(®)), a biosimilar of bevacizumab, was recently approved by the US Food and Drug Administration (FDA), which provides a less costly...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270829/ https://www.ncbi.nlm.nih.gov/pubmed/33506318 http://dx.doi.org/10.1007/s40258-021-00637-5 |